A Phase III Protocol of Androgen Suppression (AS) and 3DCTR/IMRT Vs AS and 3DCTR/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer

Trial Conditions

Prostate Cancer

What is the purpose of this trial?

RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy using
drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may fight prostate cancer
by lowering the amount of androgens the body makes. Radiation therapy uses high-energy
x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel and prednisone,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. It is not yet known whether giving hormone therapy and
radiation therapy together with chemotherapy is more effective than giving hormone therapy
together with radiation therapy in treating prostate cancer.
PURPOSE: This randomized phase III trial is studying hormone therapy and radiation therapy
followed by docetaxel and prednisone to see how well it works compared to hormone therapy
and radiation therapy in treating patients with localized prostate cancer.

Date & Status

Active, not recruiting

Who can Participate?

Eligibility

Ages:18 and older

Gender:Male

Eligibility

DISEASE CHARACTERISTICS:

- Histologically confirmed prostate cancer at high-risk for recurrence within the past 180 days as determined by 1 of the following combinations (risk groups):